However, several biomarkers have been associated with responses to anti‐PD‐1/PD‐L1 checkpoint inhibitors: microsatellite instability high status (MSI‐H),11 high tumor mutational burden (TMB‐H),12, 13 programmed death‐ligand 1 (PD‐L1) amplification and increased expression of PD‐L1 on immunohisochemistry.14, 15, 16, 17, 18. The gene discussed is CD274; the disease is neoplasm.